Background: Isolated metastatic melanoma to the pancreas is extremely rare. A recent pooled analysis evaluated 11 patients(pts) with metastatic melanoma to the pancreas and reported a median disease free interval(DFI) between the diagnosis of the primary cancer to the diagnosis of the isolated pancreatic metastasis of 48 months and a 5-year overall survival(OS) of 27%. The purpose of this study was to review our experience with resection of metastatic melanoma to the pancreas and compare it to the more common metastatic renal cell carcinoma(RCC) to the pancreas. Methods: Pts with pancreatic metastasis followed by metastasectomy were identified at a single institution from 1998 to 2013. The Kaplan-Meier method was used to report 5-year OS and disease-specific survival (DSS). Results: We identified24 pts with isolated metastasis to the pancreas that underwent curative resections. Eighteen (75%) were males and the overall median age was 64. Eleven RCC (45.8%), 4 melanomas (16.7%), and 9 other histologies (37.5%) were noted. The median DFI between the diagnosis of the primary cancer to the diagnosis of the isolated pancreatic metastasis for RCC, melanoma, and other histologies was 91.3 months (range, 2.0-361.6), 77.8 months (range, 65.3-97.4), and 55.4 months (range, 7.6-154.8) respectively. Nineteen distal pancreatectomies (79.2%) and 5 pancreaticoduodenectomies (20.8%) were performed. Five-year OS and DSS were 51% and 65%. Pts with metastatic melanoma to the pancreas had a 5-year OS of 67% (95% CI=0.05, 0.95) compared to 65% and 30% for RCC and other histologies respectively. The 5-year DSS for pts with melanoma was 67% (95% CI=0.05, 0.95) vs 100% for RCC and 34% for other histologies. After a median follow up of 39.9 months, all melanoma pts recurred after resection, with a median time to recurrence of 17.7 months. Of the 24, 10 died of disease. Conclusions: We report the largest series on pancreatic metastasectomy for melanoma. Our data show comparable DFI and survival to RCC, along with higher OS compared to previously reported data. Pancreatic metastasectomy for melanoma should be considered as evidenced by prolonged DFI and higher OS.